Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
11.64
-3.10 (-21.03%)
At close: May 9, 2025, 4:00 PM
11.75
+0.11 (0.95%)
After-hours: May 9, 2025, 6:54 PM EDT

Company Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform.

Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief.

The company’s joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions.

In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic.

Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics, Inc.
Anika Therapeutics logo
Country United States
Founded 1983
IPO Date Apr 29, 1993
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 288
CEO Cheryl Blanchard

Contact Details

Address:
32 Wiggins Avenue
Bedford, Massachusetts 01730
United States
Phone 781 457 9000
Website anika.com

Stock Details

Ticker Symbol ANIK
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000898437
CUSIP Number 035255108
ISIN Number US0352551081
Employer ID 04-3145961
SIC Code 3841

Key Executives

Name Position
Dr. Cheryl Renee Blanchard Ph.D. President, Chief Executive Officer and Director
Stephen D. Griffin Executive Vice President, Chief Financial Officer and Treasurer
David Colleran J.D. Executive Vice President, General Counsel and Corporate Secretary
Ian W. McLeod Vice President and Chief Accounting Officer
Mark Namaroff Vice President of Investor Relations, ESG and Corporate Communications
James Chase Senior Vice President of International Sales and Marketing
Ben Joseph Vice President of Commercial and Corporate Development
Lisa Funiciello Vice President of Human Resources
Mira Leiwant Senior Vice President of Regulatory, Quality and Clinical Affairs

Latest SEC Filings

Date Type Title
May 9, 2025 10-Q Quarterly Report
May 9, 2025 8-K Current Report
Apr 28, 2025 ARS Filing
Apr 28, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025 DEF 14A Other definitive proxy statements
Apr 17, 2025 SCHEDULE 13G/A Filing
Apr 10, 2025 8-K Current Report
Mar 17, 2025 10-K Annual Report
Mar 12, 2025 8-K Current Report
Mar 11, 2025 8-K Current Report